Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 26 2017 - 4:05PM
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it
will report its third quarter 2017 financial results and provide a
corporate update on November 2, 2017. The Company will also host a
conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the
United States or 1-847-585-4405 internationally approximately 10
minutes before the start of the call. The passcode is
45799161.
A replay will be available through November 16,
2017 at 1-888-843-7419 from the United States and 1-630-652-3042
internationally. The passcode will be 45799161.
About Corcept Therapeutics
Incorporated
Corcept is a pharmaceutical company engaged in
the discovery, development and commercialization of drugs that
treat severe metabolic, oncologic and psychiatric disorders by
modulating the effects of cortisol. Korlym®
(mifepristone), a first-generation cortisol modulator, is the
company’s first FDA-approved medication. Corcept has discovered and
owns exclusive rights to a large portfolio of proprietary compounds
that modulate the effects of cortisol but not progesterone. The
company holds United States and foreign intellectual property
covering the composition of these selective cortisol modulators as
well as the use of cortisol modulators, including mifepristone, to
treat a wide variety of serious disorders.
CONTACT:Charles RobbChief Financial OfficerCorcept
Therapeutics650-688-8783crobb@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024